Skip to main content

Table 1 Patients’ Characteristics

From: Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study

 

N = 285

%

Gender

Male

141

50.5

Female

144

49.5

Age at surgery(Median)

25(17–37)

 

BMI(kg/m2) (Median)

22.6(19–27)

 

Disease duration (months)

48(23.7–120)

 

Smoking

Never

222

77.9

Prior

56

19.6

Current

7

2.5

Disease extent

E2 Left-side colitis

35

12.3

E3 Pancolitis

250

87.7

Disease Severity

S2 Moderate UC

199

69.8

S3 Severe UC

86

30.2

Disease activity

Acute

18

93.7

chronic

267

6.3

Medication history

Steroid

90

31.6

6-MP or MTX

196

68.8

Immunosuppressant

Non-biologics

77

27

Anti-TNF

183

64.2

Anti-TNF adding Vedolizumab

25

8.8

Operation type

Laparoscopy

209

73.3

Open

76

26.7

Operation performed

Total abdominal colectomy

+end stoma

92

32.3

Protectomy + IPAA with ileostomy

193

67.7

Preoperative labs

Leukocyte(× 103/uL) (Median)

9.4(6.6–12.5)

Platelet(×103/uL) (Median)

350(274–475)

Albumin(g/dl) (Median)

3.7(3.3–4.0)

  1. All values expressed as median (range) or n (%)
  2. BMI body mass index, 6-MP 6-mercaptopurine, MTX methotrexate, IPAA ileal pouch-anal anastomosis, TNF tumor necrosis factor